AbCellera Biologics (ABCL) Other Non-Current Assets (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Other Non-Current Assets data on file, last reported at $69.1 million in Q1 2026.

• Quarterly Other Non-Current Assets rose 12.3% year-over-year to $69.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.1 million (up 12.3% YoY) and the FY2025 annual result came in at $51.9 million, down 46.19% from the prior year.
• Other Non-Current Assets climbed to $69.1 million in Q1 2026, from $51.9 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $134.2 million in Q3 2024 to a low of $25.0 million in Q2 2022.
• A 5-year average of $73.0 million and a median of $69.1 million in 2026 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 354.43% — and 2025, when it slumped 60.46%.
• Tracing ABCL's Other Non-Current Assets over 5 years: stood at $28.1 million in 2022, then surged by 235.39% to $94.2 million in 2023, then climbed by 2.43% to $96.5 million in 2024, then plunged by 46.19% to $51.9 million in 2025, then surged by 33.09% to $69.1 million in 2026.
• The last three Other Non-Current Assets figures came in at $69.1 million (Q1 2026), $51.9 million (Q4 2025), and $53.1 million (Q3 2025), per Business Quant data.